- Conditions
- Spinal Stenosis Lumbar
- Interventions
- Decompression, coflex® Interlaminar Technology
- Procedure · Device
- Lead sponsor
- Companion Spine, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • San Luis Obispo, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 1,326
matching trials from the local directory fallback.
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer (AJCC) v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Fermented Wheat Germ Extract
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
- Interventions
- Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Liver Transplantation, Temsirolimus, Therapeutic Conventional Surgery, Vincristine Sulfate
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 133 more
- Conditions
- Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
- Interventions
- Antineoplastic Vaccine, Pembrolizumab, Sargramostim
- Biological
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- AZD9592, AZD9592 + Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Sabestomig, AZD9592 + Volrustomig, Pembrolizumab, Rilvegostomig, Sabestomig, Volrustomig
- Biological · Combination Product
- Lead sponsor
- Presage Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Aflibercept, Faricimab, RO7446603
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 70
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more
- Conditions
- Solid Tumors
- Interventions
- Olaparib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Sacramento, California + 16 more
- Conditions
- Obesity, Psoriasis
- Interventions
- Ixekizumab, Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Interventions
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 365
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
- Conditions
- Anaplastic Medulloblastoma, Medulloblastoma
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Cyclophosphamide, Filgrastim, Isotretinoin, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 22 Years
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
- Conditions
- Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
- Interventions
- Conventional Surgery, Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, Radiation Therapy, Vincristine Sulfate
- Procedure · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2026
- U.S. locations
- 147
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 113 more
- Conditions
- Obesity or Overweight
- Interventions
- AZD6234, AZD9550, Placebo comparator
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 29
- States / cities
- Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
- Conditions
- Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
- Interventions
- Dactinomycin, Doxorubicin Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery, Vincristine Sulfate
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 111 more
- Conditions
- Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Chest Radiography, Computed Tomography, Dactinomycin, Doxorubicin Hydrochloride, Echocardiography Test, Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Ultrasound Imaging, Vincristine Sulfate
- Radiation · Procedure · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2026
- U.S. locations
- 210
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
- Interventions
- Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Other · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 5,949 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 9,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Psoriasis
- Interventions
- Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit, Risankizumab-Rzaa
- Procedure · Drug
- Lead sponsor
- Jaehwan Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Sacramento, California • New York, New York
- Conditions
- Prostate Cancer
- Interventions
- AA, LHRH agonist, PBRT, PLNRT
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,792 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 444
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
- Conditions
- Inherited Retinal Diseases Caused by RPE65 Mutations, Leber Congenital Amaurosis
- Interventions
- HG004
- Drug
- Lead sponsor
- HuidaGene Therapeutics Co., Ltd.
- Industry
- Eligibility
- 6 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Sacramento, California • Houston, Texas
- Conditions
- Collagen Degeneration, Elastic Skin, Pigmentation, Sebum Deficiency, Wrinkle
- Interventions
- Topical Product: 0.025% Tretinoin oil augmented with castor oil, Topical Product: Almond Oil, Topical Product: Almond oil augmented with 0.5% Vitamin E
- Other
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Hair Thinning
- Interventions
- Oral herbal supplement, Oral placebo supplement
- Dietary Supplement
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Rosacea, Systemic Inflammation
- Interventions
- Skin Barrier Oral Supplement
- Dietary Supplement
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Acne, Melasma, Rosacea, Seborrheic Dermatitis
- Interventions
- No Intervention
- Other
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Uveitis, Posterior
- Interventions
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 23
- States / cities
- Fullerton, California • Glendale, California • Pasadena, California + 20 more